ArticleAmerican journal of cancer research2020

A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.

Davendra Sohal et al.PubMed ↗Full text ↗

No numbers read from the abstract.